China Hepatitis A Vaccine For Long Term Immune Protection Manufacturer, Supplier, Factory

Hepatitis A Vaccine For Long Term Immune Protection is an injectable inactivated whole virus vaccine. The production workflow starts by inoculating the patented LV‑8 hepatitis A virus strain into KMB17 human diploid cell culture. After virus amplification, harvesting, ultrafiltration concentration and chromatographic purification, formaldehyde treatment fully inactivates viral infectivity. Aluminum hydroxide adjuvant is then added to formulate the final milky suspension. Gentle shaking can re-suspend settled sediment before injection.

The core design target is durable active immunity. After two-dose vaccination, the immune system generates anti-HAV antibodies that persist over many years. These circulating antibodies can neutralize hepatitis A virus upon exposure, cutting down the chance of symptomatic acute hepatitis A and limiting transmission within communities.

Since the vaccine undergoes complete inactivation, no live virus remains in the finished formulation. It cannot replicate inside the human body, which removes the risk of virulence reversion. This safety characteristic makes it a preferred option for immunization programs that require stable long term immune protection for broad age groups.

Cell Substrate & Virus Strain Foundation

1. LV‑8 HAV strain: This strain was isolated and screened during the 1988 hepatitis A outbreak in China and holds national patent protection. It has stable genetic characteristics, high virus yield during cell culture and consistent immunogenicity batch after batch.

2. KMB17 human diploid cell line: Established in 1974 and fully validated for vaccine manufacturing. The cell bank has long-term safety track records, free from exogenous infectious contaminants, and meets strict biologic production standards.

3. Aluminum hydroxide adjuvant: A standard, biocompatible adjuvant that improves antigen presentation and supports sustained antibody generation to realize the goal of Hepatitis A Vaccine For Long Term Immune Protection.

Technical Data

The product is available in vial or pre-filled syringe formats. Two separate strengths are produced to match pediatric and adult immunization requirements.

Storage rules: Keep refrigerated within 2–8°C. Freezing is strictly prohibited. Freezing breaks antigen structure and permanently reduces vaccine potency. During transport and warehousing, avoid direct sunlight and high ambient temperature.

Visually inspect every unit before administration. Check for leakage, cracks, abnormal color or foreign particles. Discard the vaccine if any abnormality is found. Shake thoroughly before use to evenly mix the suspension.

Consistent batch parameters help international buyers simplify batch testing, cold chain planning and regulatory documentation for Hepatitis A Vaccine For Long Term Immune Protection.

Deployment Scenarios

This vaccine is selected for projects where sustained population immunity is the primary objective. Each use case has distinct procurement considerations and cold chain logistics requirements.

1. Long-term national and regional immunization programs: Health authorities purchase bulk vaccine stock to build baseline immunity in endemic regions, lowering the frequency of recurring hepatitis A outbreaks year after year.

2. Occupational risk group vaccination: Food handlers, laboratory workers, healthcare staff and sanitation workers can complete full two-dose immunization to maintain long term protection against HAV exposure at the workplace.

3. Pre-travel preventive vaccination: Individuals visiting high-prevalence areas can finish the vaccination series before travel, securing durable protection against HAV transmitted via contaminated water and food.

4. Institutional preventive immunization: Schools, boarding facilities and childcare institutions deploy vaccination to reduce sustained transmission cycles within closed group settings.

Buyers can select packaging options and batch sizes according to their local immunization schedules, cold chain infrastructure and distribution network capacity.

Quality Management

Manufacturing of Hepatitis A Vaccine For Long Term Immune Protection follows NMPA GMP standards. The production facility has passed official GMP inspection, with full traceability from master cell bank, virus seed culture, purification, inactivation, filling and packaging to final batch release testing.

Each finished batch completes a full set of quality validation tests. Core tests cover antigen content assay, sterility test, bacterial endotoxin test, inactivation confirmation, pH measurement and visual inspection. Batch COA documents can be provided for qualified purchasers.

AIM Honesty Biopharmaceutical Co., Ltd. maintains an independent quality control laboratory and dedicated QA team. Production personnel receive periodic training on bioprocess control and global regulatory compliance. The team also participates in international pharmaceutical exhibitions such as CPHI to communicate with regulators and vaccine distributors worldwide.

Cold chain operation guidelines are delivered alongside shipment documents, helping customers preserve vaccine potency after receiving consignments.

Immune Persistence Profile

Clinical evaluation data shows the seroconversion rate matches imported inactivated hepatitis A vaccine benchmarks, and the geometric mean antibody titer after two-dose immunization reaches favorable protective levels. Antibody concentration rises after the primary dose and increases markedly following the 6-month booster shot.

After completing the full vaccination series, recipients retain protective anti-HAV antibody levels over extended timeframes. Individual immune response varies slightly, influenced by age, baseline health and immune status. Following the recommended two-dose regimen remains essential to achieve the intended long term immune protection.

Mild local adverse reactions may appear after injection, such as temporary tenderness, redness or slight swelling at the injection site. Most symptoms resolve spontaneously without medical intervention. Severe adverse events are uncommon. Medical staff should monitor recipients for immediate hypersensitivity reactions after administration.

For public health planners, the predictable immune persistence of Hepatitis A Vaccine For Long Term Immune Protection supports multi-year disease control planning and outbreak risk forecasting.

Packaging & Shipment

The product can be supplied in vial packaging or pre-filled syringe packaging. Each individual unit carries printed batch number, expiry date, storage instruction, antigen content and product identification. Outer cartons are engineered for stackable cold chain transport and marked with temperature control warning signs.

All shipments must maintain 2–8°C cold chain conditions. The logistics department can collaborate with specialized pharmaceutical cold chain carriers for cross-border delivery. Temperature tracking logs can be provided upon request for customs clearance and local regulatory registration.

Packaging specifications can be adjusted for bulk orders. The international sales team will confirm production lead time, document checklist and shipping terms after order details are finalized. Minimum order quantity can be discussed, buyers may contact sales for formal quotation.

FAQ

Q: What supports the long-term immune effect of this vaccine?

A: The vaccine uses formaldehyde-inactivated HAV antigen combined with aluminum hydroxide adjuvant. After two-dose immunization, the body produces specific anti-HAV antibodies and establishes immune memory cells. When the immune system encounters HAV again, memory cells quickly activate antibody production. This mechanism underpins sustained protection. Full two-dose schedule is required to build this long term immune defence.

Q: Are different dosages available for children and adults?

A: Yes, separate formulations are available. The 0.5 mL pediatric dose applies for people aged 1 to 15 years old. Individuals older than 15 years use the 1.0 mL adult formulation. Both groups need two doses with a 6-month gap between primary and booster injection.

Q: What storage requirements must be followed during transit and warehousing?

A: Store and transport the vaccine at 2°C to 8°C. Freezing must never happen. Freezing destroys antigen activity and renders the product ineffective. Avoid direct sunlight and high ambient temperature.

Q: What supporting paperwork can be supplied for import registration?

A: Qualified buyers can obtain batch release certificates, GMP documentation, product specification sheets, batch COA and manufacturing supporting documents. The company’s international business team can assist customers during local import filing, and extra supporting materials can be discussed during business communication.

Q: What differentiates inactivated hepatitis A vaccine from live attenuated alternatives?

A: Inactivated vaccine does not contain live virus. There is no risk of virus recovering virulence. It uses killed viral antigen to trigger immunity and normally requires two doses. Live attenuated vaccine uses weakened live virus. The inactivated type fits wider population groups and is widely selected for programs that target long term population immunity.

Q: Can I get samples for lab testing before bulk procurement?

A: Sample requests are acceptable. Please contact our international sales team and provide your institution profile, intended application and estimated order volume. Sample supply depends on current stock status and compliance requirements.

Structure of hepatitis A virus